Cytocom, Inc. Appoints Stephen Wilson, Ph.D., as Head of Global Innovation20210420124849
Cytocom, Inc. Appoints Stephen Wilson, Ph.D., as Head of Global Innovation
April 20, 20210 comments
FORT COLLINS, Colo., April 20, 2021 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune thera...
Cytocom to Present at the Spring 2021 Virtual Oncology Investor Conference20210329125207
Cytocom to Present at the Spring 2021 Virtual Oncology Investor Conference
March 29, 20210 comments
FORT COLLINS, Colo., March 29, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, an...
Cytocom Receives FDA Clearance of IND for Phase 2 Clinical Trial of CYTO-205 as Treatment for COVID-1920210316125022
Cytocom Receives FDA Clearance of IND for Phase 2 Clinical Trial of CYTO-205 as Treatment for COVID-19
March 16, 20210 comments
FORT COLLINS, CO., March 16, 2021 /PRNewswire/ — Cytocom, Inc., a leading biopharmaceutical company creating next generation immune therapies, announc...
Cytocom to Present at the H.C. Wainwright Global Life Sciences Conference20210302143248
Cytocom to Present at the H.C. Wainwright Global Life Sciences Conference
March 2, 20210 comments
FORT COLLINS, Colo., March 2, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, ann...
Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.20210217211619
Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.
February 17, 20210 comments
FORT COLLINS, CO., and BUFFALO, NY, FEBRUARY 17, 2021 /PRNewswire/ -- Cleveland BioLabs, Inc. (NASDAQ: CBLI), an innovative biopharmaceutical company ...
Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-1920210216123315
Cytocom Updates Investigational New Drug Application for Phase 2 Clinical Trial of CYTO-205 for the Treatment of COVID-19
February 16, 20210 comments
Fort Collins, CO., February 16, 2021 /PRNewswire/ — Cytocom, Inc., a leading biopharmaceutical company creating first second-generation immune therapi...
Cytocom to Present at BIO CEO & Investor Digital Conference20210211140408
Cytocom to Present at BIO CEO & Investor Digital Conference
February 11, 20210 comments
Fort Collins, CO., Feb. 11, 2021 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, annou...
Cytocom to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week 2021”20201222125044
Cytocom to Participate in Biotech Showcase and H.C. Wainwright BioConnect 2021 During “J.P. Morgan Week 2021”
December 22, 20200 comments
WINTER PARK, Fla., Dec. 22, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company creating second generation immune therapies, annou...
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer20201110133855
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
November 10, 20200 comments
WINTER PARK, Fla., Nov. 10, 2020 /PRNewswire/ -- Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, today ...
Cytocom Strategic Vision Conference Call Reminder20201027174551
Cytocom Strategic Vision Conference Call Reminder
October 27, 20200 comments
WINTER PARK, Fla., Oct. 27, 2020 /PRNewswire/ -- Cytocom, Inc., a leading biopharmaceutical company in the area of immune-modulation, today announced ...